Illumina (ILMN) has entered a multiyear partnership with Ovation.io to develop a dataset with integrated clinical multiomic insights from 25,000 patients treated with glucagon-like peptide-1 therapies, the companies said Thursday.
The commercially available dataset is expected to help the pharmaceutical industry advance drug discovery and development, the companies said.
Under the agreement, Ovation.io will supply genome samples from its biobank, which will be sequenced by Illumina, they said.
The initial phase of the collaboration prioritized developing datasets from patients with liver and chronic kidney disease, as well as those treated with GLP-1 receptor agonists. The companies intend to scale the GLP-1 dataset moving forward.
Price: 77.84, Change: +0.24, Percent Change: +0.31
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。